Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease-Reference-Cited by-同舟云学术

Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease

Published:2024-06-08 Issue: Volume: Page:1-4
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Sgherza Nicola¹,Curci Paola¹,Di Carlo Gabriella²,Grande Domenica²,Capozzi Alessandro²,Ingravallo Giuseppe³,De Marco Luca⁴,Ferreri Paolo⁵,Musto Pellegrino¹²

Affiliation:

1. Hematology and Bone Marrow Transplantation Unit, AOUC Policlinico, Bari, Italy

2. Department of Precision and Regenerative Medicine and Ionian Area, Aldo Moro University School of Medicine, Bari, Italy

3. Section of Pathology, Department of Precision and Regenerative Medicine and Ionian Area, Aldo Moro University School of Medicine, Bari, Italy

4. Section of Radiology and Radiation Oncology, Interdisciplinary Department of Medicine, “Aldo Moro” University School of Medicine, Bari, Italy

5. Ophthalmology Unit, AOUC Policlinico, Bari, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2364049

Reference15 articles.

1. Extramedullary disease in multiple myeloma: a systematic literature review

2. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

3. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

4. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

5. Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial